



FOR IMMEDIATE RELEASE

Dover, Delaware, July 6, 2023

**Immgenuity Inc., a leading biotechnology company, is proud to announce the appointment of Major General (Retd) Kevin Leonard to its Board of Directors.**

Maj. Gen. (Retd) Kevin Leonard, is a former senior vice president of contingency operations at Vectrus (NYSE: VEC) and a former president and CEO Charleston, South Carolina-based military logistics services provider Technica. Gen. Leonard led the Military Surface Deployment Distribution Command, where he was responsible for deployment and distribution work across expeditionary missions, before he concluded his 33-year military career.

His private sector career also includes leadership roles at Fluor (NYSE: FLR) and Amazon (NYSE: AMZN). The National Defense Industrial Association recognized Leonard with its Logistician Emeritus Award in 2014 for his significant contributions to the U.S. military's logistical operations.

For Immgenuity, Gen. Leonard will be instrumental in starting a conversation with and developing a relationship with Military HIV Research Program (MHRP) and Military Infectious Diseases Research Program (MIDRP.) Gen. Leonard has led his life and military as well as civilian career with the principles of integrity, respect and responsibility and his leadership skills both in and off the service will be invaluable to Immgenuity, Inc.

As Immgenuity tries to seek a congressional consensus for its research, Gen. Leonard will be a powerful voice on the Capitol Hill to promote research on Immgenuity's IMTV014.

"We are thrilled to have General Leonard join our Board of Directors," said Dr. Sateesh Apte, Immgenuity's CEO. "His depth of leadership, corporate governance experience and strategic insights will be invaluable as we continue to develop and advance our therapeutic vaccine to address an unmet medical needs to achieve remission in HIV."

"I am extremely happy to join Immgenuity's Board of Directors and contribute to the development of Immgenuity's therapeutic vaccine that has the potential to make a significant impact on patients' lives," said Gen. Leonard.

"Immgenuity's innovative approach to achieving a remission in HIV and its focus on addressing this unmet medical need aligns with my own values and passion for forward progress in healthcare."

Immgenuity's Board of Directors is composed of world-renowned experts in the fields of leadership, management and corporate governance. The Board provides guidance and strategic advice to Immgenuity's leadership team on operations and strategies of the company.

### **About Immgenuity**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit

<https://immgenuity.com>

## **About IMTV014**

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

## **Forward Looking Statements:**

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.